We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amphastar Pharmaceuticals Inc | NASDAQ:AMPH | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.20 | -0.47% | 42.46 | 42.00 | 44.89 | 43.1286 | 42.03 | 42.99 | 353,239 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Amphastar Pharmaceuticals Inc. (AMPH) Wednesday said it will receive nearly $60 million from Momenta Pharmaceuticals Inc. (MNTA) and a unit of Novartis AG (NVS) after the companies agreed to settle their long-running litigation related to generic versions of the blood-thinner Lovenox.
Amphastar, a Rancho Cucamonga, Calif., specialty pharmaceutical company, said Novartis' Sandoz and Momenta will pay $59.9 million by July 2 as part of the settlement, under which the companies will dismiss all pending litigation.
Momenta and its partner Sandoz filed a patent-infringement suit against Amphastar in 2011, seeking more than $900 million in damages, after the U.S. Food and Drug Administration approved Amphastar's generic version of Sanofi's (SNY) Lovenox. Amphastar later countered with an antitrust suit against Momenta and Sandoz.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 19, 2019 07:37 ET (11:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Amphastar Pharmaceuticals Chart |
1 Month Amphastar Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
